Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP) Guideline update 2025

Authors

DINIS-RIBEIRO Mário LIBÂNIO Diogo UCHIMA Hugo SPAANDER Manon C W BORNSCHEIN Jan MATYSIAK-BUDNIK Tamara TZIATZIOS Georgios SANTOS-ANTUNES Joao AREIA Miguel CHAPELLE Nicolas ESPOSITO Gianluca FERNANDEZ-ESPARRACH Gloria KUNOVSKÝ Lumír GARRIDO Mónica TACHECI Ilja LINK Alexander MARCOS Pedro MARCOS-PINTO Ricardo MOREIRA Leticia PEREIRA Ana Carina PIMENTEL-NUNES Pedro ROMANCZYK Marcin FONTES Filipa HASSAN Cesare BISSCHOPS Raf FEAKINS Roger SCHULZ Christian TRIANTAFYLLOU Konstantinos CARNEIRO Fatima KUIPERS Ernst J

Year of publication 2025
Type Article in Periodical
Magazine / Source Endoscopy
MU Faculty or unit

Faculty of Medicine

Citation
web https://www.esge.com/management-of-epithelial-precancerous-conditions-and-early-neoplasia-of-the-stomach-maps-iii-esge-ehmsg-esp-guideline-update-2025
Doi http://dx.doi.org/10.1055/a-2529-5025
Keywords early neoplasia of the stomach; epithelial precancerous conditions
Description At a population level, the European Society of Gastrointestinal Endoscopy (ESGE), the European Helicobacter and Microbiota Study Group (EHMSG), and the European Society of Pathology (ESP) suggest endoscopic screening for gastric cancer (and precancerous conditions) in high-risk regions (age-standardized rate [ASR] > 20 per 100 000 person-years) every 2 to 3 years or, if cost–effectiveness has been proven, in intermediate risk regions (ASR 10–20 per 100 000 person-years) every 5 years, but not in low-risk regions (ASR < 10). ESGE/EHMSG/ESP recommend that irrespective of country of origin, individual gastric risk assessment and stratification of precancerous conditions is recommended for first-time gastroscopy. ESGE/EHMSG/ESP suggest that gastric cancer screening or surveillance in asymptomatic individuals over 80 should be discontinued or not started, and that patients’ comorbidities should be considered when treatment of superficial lesions is planned.

You are running an old browser version. We recommend updating your browser to its latest version.

More info